|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?
|
31556355 |
2020 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In patients with FDG-avid lymphomas, such as diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL), <sup>18</sup> F-FDG-PET/CT remains the imaging reference standard for staging, with WB-MRI potentially being a complementary modality that could replace CT, especially in young patients.
|
31486520 |
2020 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG PET/CT) is currently the criterion standard of lymphoma imaging and recommended through all stages of Hodgkin lymphoma management.
|
30247256 |
2019 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Parapharyngeal Ganglioneuroma Detected by 18F-FDG PET/CT in a Patient With Hodgkin Lymphoma.
|
30672755 |
2019 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a retrospective cohort study, we analysed cardiac and skeletal muscle <sup>18</sup> F-FDG uptake in onco-positron emission tomography-computed tomography scans in adult patients suffering from Hodgkin's lymphoma, non-Hodgkin's lymphoma, and non-lymphatic cancer including patients suffering from thyroid cancer, bronchial carcinoma, and malignant melanoma.
|
31278857 |
2019 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>18</sup>F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors.
|
30032683 |
2019 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The main objective of the present study was to examine quantitatively the effects of chemotherapy on brain metabolism in a homogeneous population of children treated for Hodgkin's lymphoma using 18F-FDG PET/CT.
|
31087250 |
2019 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic Value of Pretreatment Radiomic Features of 18F-FDG PET in Patients With Hodgkin Lymphoma.
|
31306204 |
2019 |
|
Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thirty-five patients diagnosed with HL who underwent <sup>18</sup>F-FDG PET/CT scans before and during chemotherapy were retrospectively enrolled in this investigation.
|
31761665 |
2019 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We present the results of an investigation of the role of FDG PET in response evaluation of bulky masses in paediatric patients with Hodgkin's lymphoma (HL) enrolled in the Italian AIEOP-LH2004 trial.
|
30219963 |
2019 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Quantitative assessment of 18F-FDG PET in patients with Hodgkin lymphoma: is it significantly affected by contrast-enhanced computed tomography attenuation correction?
|
30461699 |
2019 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
There was no significant difference in F-FDG metabolic parameters, IPS, and other risk indicators between HIV-infected and HIV-uninfected patients with Hodgkin lymphoma.
|
30198974 |
2018 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Functional imaging using 18-fluorodeoxyglycose ([<sup>18</sup>F]FDG) positron emission tomography combined with computed tomography (PET/CT) has become a major imaging modality in Hodgkin lymphoma.
|
29783621 |
2018 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In terms of staging, the meta-analytic staging accuracies of WB-MRI and <sup>18</sup>F-FDG PET/CT for Hodgkin lymphoma and aggressive non-Hodgkin lymphoma (NHL) were 98% (95% CI, 94%-100%) and 98% (95% CI, 94%-100%), respectively.
|
29950864 |
2018 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we present the findings of a whole-body <sup>18</sup>FDG PET/CT with extensive and multifocal involvement of the GIT in a patient that developed severe acute GVHD 93 days post autologous SCT for Hodgkin's lymphoma.
|
30326627 |
2018 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
To determine whether the current <sup>18</sup>F-FDG PET response criterion for skeletal involvement in Hodgkin lymphoma (HL) is suitable, we performed a systematic evaluation of the different types of skeletal involvement and their response on PET after 2 cycles of chemotherapy (PET-2).
|
29653979 |
2018 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated the accuracy of 3-mo <sup>18</sup>F-FDG PET/CT for the identification of HL patients responding to immune-checkpoint blockade by anti-programmed death 1 antibodies (anti-PD1).
|
28596157 |
2018 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Testicular Estrogen-Secreting Leydig Cell Tumor in 18F-FDG PET/CT: An Incidental Detection in a Patient Treated by Chemotherapy for Hodgkin Lymphoma.
|
29166332 |
2018 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lactate dehydrogenase (LDH) and F-FDG PET/CT-based maximum tumor diameter, lesion-to-liver ratio maximum standardized uptake value (SUVmax), and lesion-to-liver ratio peak standardized uptake value (SUVpeak) were all significantly higher (P<0.001) in PMBCL than in Hodgkin's lymphoma, and PMBCL also significantly more frequently (P=0.001) exhibited necrosis on F-FDG PET/CT than Hodgkin's lymphoma.
|
29672465 |
2018 |
|
Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A 15-year-old girl with Hodgkin lymphoma in the neck underwent follow-up FDG PET/CT scan to monitor the response to the chemotherapy.
|
30153146 |
2018 |
|
Hodgkin Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To determine whether, in patients with Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL), [<sup>18</sup>F]FDG PET/MR can capture treatment effects within the first week after treatment initiation, and whether changes in glucose metabolism and cell density occur simultaneously.
|
29480328 |
2018 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
A 15-year-old girl with Hodgkin disease underwent staging FDG PET/CT, which revealed not only the abnormal activity in the lymph nodes and left ilium, which were consistent with the malignant involvement, but also increased activity in the gallbladder.
|
29485432 |
2018 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ninety-one patients were randomized to ceCT64 and 90 to FDG PET/ceCT; 72 had Hodgkin lymphoma, 72 had DLBCL, and 37 had follicular lymphoma.
|
28604477 |
2017 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> We confirmed that <sup>18</sup>F-FDG PET scanning is a reliable tool for BMI assessment in HL, and BM biopsy is no longer needed for routine staging.
|
28126883 |
2017 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results imply that low myocardial <sup>18</sup>F-FDG uptake before the initiation of doxorubicin chemotherapy in HD patients may predict the development of chemotherapy-induced cardiotoxicity, suggesting that prospective clinical trials are warranted to test this hypothesis.
|
28646013 |
2017 |